Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen, Inc.

Show Me the Data™: Making Informed Treatment Decisions for Patients with Immune Thrombocytopenia (ITP)

Release Date: January 22, 2021
Expiration Date: January 22, 2022

Activity Overview

The clinical presentation and course of immune thrombocytopenia (ITP) is heterogeneous and variable in adults and also differs between children and adults. Advances in treatment strategies, including emerging therapies for adult and pediatric patients with ITP, raise challenging questions for oncologists and hematologists. Clinicians must be able to diagnose ITP and individualize treatment for each patient while minimizing treatment-associated toxicities.

Clinicians are challenged to put new information into clinical context, as they are often not up-to-date with the latest data from clinical studies, leading to delays in adopting evidence-driven changes in treatment options and patient-management strategies. Educational activities that update oncologists and hematologists on new information and advances in treatment strategies and provide guidance on integrating these advances into their practice are necessary to optimize care for individual patients. At the conclusion of this activity, participants will be able to identify patients with ITP who need treatment, evaluate recent clinical data for approved and investigational treatments, and apply current clinical recommendations for the management of ITP.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen, Inc.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward hematologists, hematology-oncologists, pathologists, and other oncology health care professionals who treat patients with ITP. Hematologists, hematology-oncologists, pathologists, and other oncology health care professionals, as well as other health care professionals interested in the treatment of ITP are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:
1. Explain the pathophysiology underlying chronic ITP that has led to the development of targeted therapy
2. Outline diagnostic recommendations for ITP and strategies to differentiate ITP from other disorders with similar presentation
3. Consider recent clinical data of efficacy and safety profiles of current and emerging therapeutic strategies for ITP treatment
4. Integrate recent evidence to inform personalized clinical decision-making in the management of ITP

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Craig M. Kessler, MD, MACP
Professor of Medicine and Pathology
Director, Division of Coagulation
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, DC

Disclosures:  Grant/Research Support: Octapharma, Takeda Pharmaceutical Company; Consultant: CSL Behring, Octapharma, Takeda Pharmaceutical Company; Other Support: Director, 340B Program at Hemophilia Treatment Centers, Novartis Pharmaceuticals, Rigel Pharmaceuticals.

Ivy Altomare, MD
Associate Professor of Medicine
Division of Medical Oncology
Duke University School of Medicine
Medical Oncologist
Duke Cancer Network
Durham, NC

Disclosures:  Consultant: Rigel Pharmaceuticals, Amgen, Novartis Pharmaceuticals, Dova Pharmaceuticals, Argenex

Jenny M. Despotovic, DO
Associate Professor of Pediatrics
Baylor College of Medicine
Director, Hematology Center
Director, Immune Hematology Program
Texas Children’s Hospital
Houston, TX

Disclosures: Grant/Research Support: Novartis Pharmaceuticals; Consultant: Novartis Pharmaceuticals, Amgen, Agios Pharmaceuticals, Dova Pharmaceuticals; Other Support: Royalty Pharma.

Howard A. Liebman, MD, MA
Professor of Medicine and Pathology
Keck School of Medicine of USC
Donald I. Feinstein Chair in Hematology
Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Disclosures: Grant/Research Support: Argenx, Novartis, Syntimmune, Inc, Pfizer; Consultant: Amgen, Rigel Pharmaceuticals, Bristol Myers Squibb, Alexion Pharmaceuticals, Dova Pharmaceuticals.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.